The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving care for patients with stage III/IV NSCLC: Learnings for multidisciplinary teams from the ACCC national quality survey.
 
Ravi Salgia
Consulting or Advisory Role - Abbvie; ARIAD; Iovance Biotherapeutics; Novartis; Octimet
Speakers' Bureau - AstraZeneca; Merck
 
Leigh Boehmer
No Relationships to Disclose
 
Catherine Celestin
Employment - AstraZeneca; AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Judy Yu
Employment - AstraZeneca
Stock and Other Ownership Interests - Abbott; AstraZeneca; Becton Dickinson; Bristol-Myers Squibb; Stryker
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Merck (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst); Williams and Connolly (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Takeda (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Takeda